Drug Trial Radar · NCT03395197
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,054
Actual
Start
Dec 18, 2017
Primary completion
Oct 3, 2022
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc
- First posted
- Jan 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Conditions
- mCRPC
Interventions
Talazoparib with enzalutamideDrug
Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
Placebo with enzalutamideDrug
Placebo plus enzalutamide 160 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1Time frame: Post dose on Day 1 up to Day 66 in Part 1
- Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1Time frame: Post dose on Day 1 up to Day 66 in Part 1
- Number of Participants With All-Causality TEAEs During the Overall Period of Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
- Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
- Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
- Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
- Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)
- BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)
Locations
370 sites in 26 countries. Site status is shown where the registry gives one.
Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, Alaska
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Chandler, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Gilbert, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Mesa, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Mesa, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Scottsdale, Arizona
Arizona Urology Specialists
Tucson, Arizona
Arizona Urology Specialists
Tucson, Arizona
Beverly Hills Cancer Center
Beverly Hills, California
South County Hematology/Oncology
Chula Vista, California
Sharp Rees-Stealy
Chula Vista, California
Glendale Adventist Medical Center
Glendale, California
Marin Cancer Care, Inc.
Greenbrae, California
Cancer Center Oncology Medical Group
La Mesa, California
Loma Linda University Cancer Center - Records Management Only
Loma Linda, California
Loma Linda University Cancer Center - Hematology/Oncology Clinic
Loma Linda, California
Loma Linda University Medical Center
Loma Linda, California
VA Long Beach Healthcare System
Long Beach, California
UCLA Clark Urology Center
Los Angeles, California
University of California, Irvine Medical Center
Orange, California
Stanford Cancer Institute
Palo Alto, California
Desert Hematology Oncology Medical Group, Incorporation
Rancho Mirage, California
Eisenhower Medical Center
Rancho Mirage, California
Medical Oncology Associates-SD
San Diego, California
Sharp Memorial Hospital Investigational Pharmacy
San Diego, California
Sharp Rees-Stealy
San Diego, California
Stanford Health Care
Stanford, California
University of Colorado Denver CTO/CTRC
Aurora, Colorado
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
University of Colorado Hospital- Anschutz Inpatient Pavilion
Aurora, Colorado
University of Colorado Hospital- Anschutz Outpatient Pavilion
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
The Urology Center of Colorado
Denver, Colorado
Florida Cancer Specialists
Altamonte Springs, Florida
Florida Cancer Specialists
Brandon, Florida
Florida Cancer Specialists
Clearwater, Florida
Florida Cancer Specialists
Daytona Beach, Florida
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists
Gainesville, Florida
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida
Showing 40 of 370 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.